GNS vs UTI: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
UTI is the larger of the two ($2.16B market cap): the incumbent the market prices for continued execution (42.27x forward earnings, beta 1.23). GNS is the smaller challenger ($28.41M), priced similarly on forward earnings (-3.70x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
GNS vs UTI: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GNS | UTI | What it tells you |
|---|---|---|---|
| Market cap | $28.41M | $2.16B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -3.70 | 42.27 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 9.21 | 1.23 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 0% of range | 60% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.27 | 6.37 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how GNS and UTI affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GNS and UTI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GNS and UTI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Genius Group Limited (GNS) do?
Genius Group Limited is a Singapore-based education-technology company listed on NYSE American under the ticker GNS. It describes itself as an AI-powered education and acceleration group, delivering learning through business units it has organized as Genius School (an AI-powered curriculum from preschool through high school), Genius Academy (accelerated programs for adults in entrepreneurship, investing, and emerging technology), and Genius Resorts (resorts and beach clubs positioned as physical learning centers). A fourth unit, Genius City, is under development with a target completion in 2027. The company reports serving millions of users across more than 100 countries.
What does Universal Technical Institute (UTI) do?
Universal Technical Institute, Inc. (NYSE: UTI) runs postsecondary vocational schools across two reportable segments. The legacy UTI segment trains students in automotive, diesel, motorcycle, marine, welding, CNC and related skilled trades, while the Concorde Career Colleges segment (acquired in 2022) offers allied health, dental, nursing, patient-care and diagnostic programs. The company generates revenue primarily from student tuition, much of it funded through federal Title IV financial aid, and it has been growing student starts and average full-time enrollment at both segments.
GNS vs UTI: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- GNS drivers: AI-powered education growth off a small base; Treasury strategy pivot.
- UTI drivers: Skilled-trades demand tailwind; Concorde and healthcare diversification.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The overriding risk is that Genius Group is a speculative micro-cap: its small size means thin trading, wide price swings, and outsized sensitivity to any single corporate announcement. For UTI, uTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business.
GNS or UTI: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GNS if you believe its drivers more; UTI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GNS and UTI guides.
GNS vs UTI: the full fundamentals
GNS. All figures are approximate, tied to the asOf date, and drawn from company statements and secondary sources; verify live numbers before acting. For a micro-cap like Genius Group, traditional valuation multiples are of limited use because reported profits are small, recent, and can be affected by one-time items, treasury gains or losses, and legal outcomes. The share price can move far more on corporate-action and litigation news than on operating results, so any valuation view here is highly uncertain.
UTI. Fiscal 2025 revenue grew about 14% and net income rose roughly 50% to about $63 million. Fiscal 2026 guidance calls for revenue near $905 to $915 million but net income of only about $40 to $45 million, reflecting roughly $40 million of growth-investment spending. The premium P/E reflects investor expectations that campus expansion will lift future earnings.
Headline figures (approximate, Jul 2026): GNS shows market cap Micro-cap, reported in the low tens of millions of dollars (roughly ~$30 million range in mid-2026); verify live, revenue (2026 guidance) Company guided to roughly $20 million to $22 million, up meaningfully from about $13.5 million in 2025, adjusted ebitda (2026 guidance) Management pointed to modest positive adjusted EBITDA from operations, in the low single-digit millions, profitability Reported early operational profitability in recent quarters, but off a very small base and subject to audit; UTI shows revenue (fy2025) ~$835.6M, revenue guidance (fy2026) ~$905-915M, net income (fy2025) ~$63M, adjusted ebitda (fy2025) ~$126.5M.
The bottom line: GNS vs UTI
GNS and UTI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GNS and UTI exposure against your real portfolio. It is not an investment adviser.
Wondering how GNS or UTI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Genius Group Limited with AI
Connect the broker you already use and ask Walnut's AI how GNS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between GNS and UTI?
+
Genius Group Limited is a Singapore-based education-technology company listed on NYSE American under the ticker GNS. Universal Technical Institute, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GNS or UTI the better stock?
+
Neither is universally better. UTI is the larger incumbent; GNS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GNS or UTI?
+
On forward P/E (as of August 2026), GNS trades at -3.70x and UTI at 42.27x, so GNS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GNS and UTI?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GNS vs UTI?
+
GNS: The overriding risk is that Genius Group is a speculative micro-cap: its small size means thin trading, wide price swings, and outsized sensitivity to any single corporate announcement. Litigation is a major overhang, with reported arbitration and class-action exposure that could result in cash awards or share issuance and is largely outside the company's control. The treasury pivots (from Bitcoin toward AI-focused and digital-banking bets) add balance-sheet uncertainty and tie part of the story to volatile crypto-adjacent themes rather than to teaching. The history of dilution and capital raises means existing holders can be diluted again if the company needs funding. Reported profitability is early and off a low base, so it may not prove durable. As a foreign private issuer, disclosure cadence and governance can differ from typical US companies, another reason to size any position cautiously. UTI: UTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business. Near-term profitability has already collapsed on expansion spending, and the stock's premium multiple leaves little room for disappointment if new campuses underperform or enrollment growth stalls. The for-profit education sector carries a history of regulatory scrutiny and reputational risk. Rising labor and real-estate costs can pressure margins, and an economic downturn can cut both ways on enrollment. Any softening in student starts or graduate placement rates would challenge the growth narrative underpinning the current valuation.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GNS or UTI; figures are approximate and dated (as of August 2026). Verify current data before investing.